Search

Your search keyword '"Atzori F."' showing total 336 results
Start Over Author "Atzori F."
336 results on '"Atzori F."'

1. Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology

Author

Agostinetto, E., Bruzzone, M., Hamy, A.-S., Kim, H.J., Chiodi, C., Bernstein-Molho, R., Linn, S., Pogoda, K., Carrasco, E., Derouane, F., Bajpai, J., Nader-Marta, G., Lopetegui-Lia, N., Partridge, A.H., Cortesi, L., Rousset-Jablonski, C., Giugliano, F., Renaud, T., Ferrari, A., Paluch-Shimon, S., Fruscio, R., Cui, W., Wong, S.M., Vernieri, C., Ruddy, K.J., Dieci, M.V., Matikas, A., Rozenblit, M., Aguilar y Mendez, D., De Marchis, L., Borea, R., Puglisi, F., Pistelli, M., Kufel-Grabowska, J., Di Rocco, R., Mariamidze, E., Atzori, F., Kourie, H.R., Popovic, L., de Azambuja, E., Blondeaux, E., and Lambertini, M.

Published
2024
Full Text
View/download PDF

3. An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study

Author

Internò, V., Massari, F., Rudà, R., Maiorano, B.A., Caffo, O., Procopio, G., Bracarda, S., Atzori, F., Passarelli, A., Bersanelli, M., Stellato, M., Fornarini, G., Galli, L., Ortega, C., Zanardi, E., Incorvaia, L., Facchini, G., Giron Berrios, J.R., Ricotta, R., Santoni, M., Funaioli, C., Trerotoli, P., Porta, C., and Rizzo, M.

Published
2023
Full Text
View/download PDF

4. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program

Author

Rebuzzi, S.E., Signori, A., Buti, S., Banna, G.L., Murianni, V., Damassi, A., Maruzzo, M., Giannarelli, D., Tortora, G., Galli, L., Rizzo, M., De Giorgi, U., Antonuzzo, L., Bracarda, S., Cartenì, G., Atzori, F., Tamberi, S., Procopio, G., Fratino, L., Lo Re, G., Santoni, M., Baldessari, C., Astone, A., Calabrò, F., Brunelli, M., Porta, C., Rescigno, P., Basso, U., and Fornarini, G.

Published
2022
Full Text
View/download PDF

7. Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology

Author

Agostinetto, E, Bruzzone, M, Hamy, A, Kim, H, Chiodi, C, Bernstein-Molho, R, Linn, S, Pogoda, K, Carrasco, E, Derouane, F, Bajpai, J, Nader-Marta, G, Lopetegui-Lia, N, Partridge, A, Cortesi, L, Rousset-Jablonski, C, Giugliano, F, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Ruddy, K, Dieci, M, Matikas, A, Rozenblit, M, Aguilar Y Mendez, D, De Marchis, L, Borea, R, Puglisi, F, Pistelli, M, Kufel-Grabowska, J, Di Rocco, R, Mariamidze, E, Atzori, F, Kourie, H, Popovic, L, de Azambuja, E, Blondeaux, E, Lambertini, M, Hamy, A-S, Kim, H J, Partridge, A H, Wong, S M, Ruddy, K J, Dieci, M V, Kourie, H R, Agostinetto, E, Bruzzone, M, Hamy, A, Kim, H, Chiodi, C, Bernstein-Molho, R, Linn, S, Pogoda, K, Carrasco, E, Derouane, F, Bajpai, J, Nader-Marta, G, Lopetegui-Lia, N, Partridge, A, Cortesi, L, Rousset-Jablonski, C, Giugliano, F, Renaud, T, Ferrari, A, Paluch-Shimon, S, Fruscio, R, Cui, W, Wong, S, Vernieri, C, Ruddy, K, Dieci, M, Matikas, A, Rozenblit, M, Aguilar Y Mendez, D, De Marchis, L, Borea, R, Puglisi, F, Pistelli, M, Kufel-Grabowska, J, Di Rocco, R, Mariamidze, E, Atzori, F, Kourie, H, Popovic, L, de Azambuja, E, Blondeaux, E, Lambertini, M, Hamy, A-S, Kim, H J, Partridge, A H, Wong, S M, Ruddy, K J, Dieci, M V, and Kourie, H R

Abstract

Background: Young women with breast cancer (BC) have an increased chance of carrying germline BRCA pathogenic variants (PVs). Limited data exist on the prognostic impact of tumor histology (i.e. ductal versus lobular) in hereditary breast cancer. Methods: This multicenter retrospective cohort study included women aged ≤40 years with early-stage breast cancer diagnosed between January 2000 and December 2020 and known to carry germline PVs in BRCA1/2. Histology was locally assessed in each center. The Kaplan-Meier method and Cox regression analysis were used to assess disease-free survival and overall survival. Results: Of 4628 patients included from 78 centers worldwide, 3969 (86%) had pure ductal, 135 (3%) pure lobular, and 524 (11%) other histologies. Compared with ductal tumors, lobular tumors were more often grade 1/2 (57.7% versus 22.1%), stage III (29.6% versus 18.5%), and luminal A-like (42.2% versus 12.2%). Lobular tumors were more often associated with BRCA2 PVs (71.1% BRCA2), while ductal tumors were more often associated with BRCA1 PVs (65.7% BRCA1). Patients with lobular tumors more often had mastectomy (68.9% versus 58.3%), and less often received chemotherapy (83.7% versus 92.9%). With a median follow-up of 7.8 years, no significant differences were observed in disease-free survival (adjusted hazard ratio 1.01, 95% confidence interval 0.74-1.37) or overall survival (hazard ratio 0.96, 95% confidence interval 0.62-1.50) between patients with ductal versus lobular tumors. No significant survival differences were observed according to specific BRCA gene, breast cancer subtype, or body mass index. Conclusions: In this large global cohort of young BRCA carriers with breast cancer, the incidence of pure lobular histology was low and associated with higher disease stage at diagnosis, luminal-like disease and BRCA2 PVs. Histology did not appear to impact prognosis.

Published
2024

8. Neoadjuvant versus adjuvant chemotherapy in muscle-invasive bladder cancer: The RealBLADDER study. Results on behalf of the GOIRC

Author

Gambale, E., primary, GIORGIONE, R., additional, VASCOTTO, I.A., additional, DE GENNARO AQUINO, I., additional, SCOLARI, F., additional, MELA, M.M., additional, CATALANO, M., additional, ROVIELLO, G., additional, DONI, L., additional, GALLI, L., additional, BALDAZZI, V., additional, ATZORI, F., additional, MASINI, C., additional, SCAGLIARINI, S., additional, PILLOZZI, S., additional, BASSO, U., additional, and ANTONUZZO, L., additional

Published
2023
Full Text
View/download PDF

10. Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

Author

Alù, M., Ancona, C., Andreis, D., Bajardi, E., Benedetto, C., Berardi, R., Bordin, E., Butti, C., Capri, G., Cicchiello, F., Cocciolone, V., Dester, M., D'Onofrio, L., Febbraro, A., Ferrarini, I., Fotia, V., Gervasi, E., Guaitoli, G., Licata, L., Liscia, N., Mentuccia, L., Miraglio, E., Nicolini, M., Paternò, E., Pedani, F., Pellegrini, D., Petrucelli, L., De Laurentiis, M., Pizzuti, L., Pogliani, C., Riva, F., Cazzaniga, M.E., Airoldi, M., Arcangeli, V., Artale, S., Atzori, F., Ballerio, A., Bianchi, G.V., Blasi, L., Campidoglio, S., Ciccarese, M., Cursano, M.C., Piezzo, M., Fabi, A., Ferrari, L., Ferzi, A., Ficorella, C., Frassoldati, A., Fumagalli, A., Garrone, O., Gebbia, V., Generali, D., La Verde, N., Maur, M., Michelotti, A., Moretti, G., Musolino, A., Palumbo, R., Pistelli, M., Porpiglia, M., Sartori, D., Scavelli, C., Schirone, A., Turletti, A., Valerio, M.R., Vici, P., Zambelli, A., Clivio, L., and Torri, V.

Published
2017
Full Text
View/download PDF

11. Morphostructural Characterization of the Heterogeneous Rhodolith Bed at the Marine Protected Area “Capo Carbonara” (Italy) and Hydrodynamics

Author

Bracchi, V, Caronni, S, Meroni, A, Burguett, E, Atzori, F, Cadoni, N, Marchese, F, Basso, D, Bracchi V. A., Caronni S., Meroni A. N., Burguett E. G., Atzori F., Cadoni N., Marchese F., Basso D., Bracchi, V, Caronni, S, Meroni, A, Burguett, E, Atzori, F, Cadoni, N, Marchese, F, Basso, D, Bracchi V. A., Caronni S., Meroni A. N., Burguett E. G., Atzori F., Cadoni N., Marchese F., and Basso D.

Abstract

Mediterranean rhodolith beds are priority marine benthic habitats for the European Com-munity, because of their relevance as biodiversity hotspots and their role in the carbonate budget. Presently, Mediterranean rhodolith beds typically occur within the range of 30–75 m of water depth, generally located around islands and capes, on flat or gently sloping areas. In the framework of a collaboration between the University of Milano-Bicocca and the Marine Protected Area “Capo Carbonara” (Sardinia, Italy), video explorations and sampling collections in three selected sites revealed the occurrence of a well developed and heterogeneous rhodolith bed. This bed covers an area >41 km2 around the cape, with live coverage ranging between 6.50 and 55.25%. Rhodoliths showed interesting morphostructural differences. They are small compact pralines at the Serpentara Island, associated with gravelly sand, or bigger boxwork at the Santa Caterina shoal associated with sand, whereas branches are reported mostly in the Is Piscadeddus shoal, associated with muddy sand. Both in the Santa Caterina shoal and the Serpentara Island, rhodoliths generally show a spheroidal shape, associated with a mean value of currents of 4.3 and 7.3 cm/s, respectively, up to a maximum of 17.7 cm/s at Serpentara, whereas in the Is Piscadeddus shoal rhodolith shape is variable and current velocity is significantly lower. The different hydrodynamic regime, with a constant current directed SW, which deviates around the cape towards E, is responsible for such morphostructural heterogeneity, with the site of the Serpentara Island being the most exposed to a constant unidirec-tional and strong current. We can associate current velocity with specific rhodolith morphotypes. The morphostructural definition of the heterogeneity of rhodoliths across large beds must be considered for appropriate management policies.

Published
2022

13. Caulerpa cylindracea Spread on Deep Rhodolith Beds Can Be Influenced by the Morphostructural Composition of the Bed

Author

Caronni, S, Bracchi, V, Atzori, F, Citterio, S, Cadoni, N, Gentili, R, Montagnani, C, Quaglini, L, Basso, D, Caronni, Sarah, Bracchi, Valentina Alice, Atzori, Fabrizio, Citterio, Sandra, Cadoni, Nicoletta, Gentili, Rodolfo, Montagnani, Chiara, Quaglini, Lara Assunta, Basso, Daniela, Caronni, S, Bracchi, V, Atzori, F, Citterio, S, Cadoni, N, Gentili, R, Montagnani, C, Quaglini, L, Basso, D, Caronni, Sarah, Bracchi, Valentina Alice, Atzori, Fabrizio, Citterio, Sandra, Cadoni, Nicoletta, Gentili, Rodolfo, Montagnani, Chiara, Quaglini, Lara Assunta, and Basso, Daniela

Abstract

The green alga Caulerpa cylindracea Sonder (Chlorophyta; Bryopsidales) is one of the most invasive alien macroalgae in the Mediterranean Sea, where it is also spreading on rhodolith beds, an important biogenic assemblage typical of deep substrates. Despite the importance of rhodoliths, data on the competitive interactions with C. cylindracea are still scarce. To deepen the knowledge on the topic, C. cylindracea occurrence on the rhodolith bed of Capo Carbonara Marine Protected Area (Italy) was explored. Quantitative analyses of videoframes obtained from Remote Operated Vehicle records in three different MPA sites, Is Piscadeddus, Santa Caterina, and Serpentara, allow for estimates of both the cover of rhodoliths (considering the main morphotypes) and of C. cylindracea, as well as their competition. All sites showed a well-developed rhodolith bed, although some differences were highlighted in their composition in terms of morphotype, shape, and dimension of rhodoliths, as well as in the C. cylindracea cover. In particular, Santa Caterina appeared to be the site with the highest mean total cover of rhodoliths (68%), and of C. cylindracea (25%). The obtained results suggest that different competitive interactions occur between C. cylindracea and rhodolith beds, in relation to the morphostructural composition of the latter and in response to environmental conditions that affect rhodolith bed composition.

Published
2023

14. 118P Immunosenescence and response to immunotherapy in elderly patients: A possible prognostic tool

Author

Pretta, A., primary, Donisi, C., additional, Ziranu, P., additional, Liscia, N., additional, Loi, F., additional, Saba, G., additional, Pretta, G., additional, Spanu, D., additional, Dubois, M., additional, Atzori, F., additional, Pusceddu, V., additional, Puzzoni, M., additional, Massa, E., additional, Madeddu, C., additional, Lai, E., additional, Astara, G., additional, and Scartozzi, M., additional

Published
2022
Full Text
View/download PDF

15. Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies

Author

Cazzaniga, M, Verusio, C, Ciccarese, M, Fumagalli, A, Sartori, D, Valerio, M, Airoldi, M, Moretti, G, Ficorella, C, Gianni, L, Michelotti, A, Zambelli, A, Febbraro, A, Generali, D, Pistelli, M, Garrone, O, Musolino, A, Vici, P, Maur, M, Mentuccia, L, La Verde, N, Bianchi, G, Artale, S, Blasi, L, De Laurentiis, M, Atzori, F, Turletti, A, Porpiglia, M, Santini, D, Fabi, A, Gebbia, V, Schirone, A, Palumbo, R, Ferzi, A, Frassoldati, A, Scavelli, C, Clivio, L, Giordano, M, Donadio, M, Biganzoli, L, Del Mastro, L, Bisagni, G, Livi, L, Natoli, C, Montemurro, F, Riccardi, F, Romagnoli, E, Marchetti, P, Torri, V, Pronzato, P, Mustacchi, G, Cazzaniga M. E., Verusio C., Ciccarese M., Fumagalli A., Sartori D., Valerio M. R., Airoldi M., Moretti G., Ficorella C., Gianni L., Michelotti A., Zambelli A., Febbraro A., Generali D., Pistelli M., Garrone O., Musolino A., Vici P., Maur M., Mentuccia L., La Verde N., Bianchi G. V., Artale S., Blasi L., De Laurentiis M., Atzori F., Turletti A., Porpiglia M., Santini D., Fabi A., Gebbia V., Schirone A., Palumbo R., Ferzi A., Frassoldati A., Scavelli C., Clivio L., Giordano M., Donadio M., Biganzoli L., Del Mastro L., Bisagni G., Livi L., Natoli C., Montemurro F., Riccardi F., Romagnoli E., Marchetti P., Torri V., Pronzato P., Mustacchi G., Cazzaniga, M, Verusio, C, Ciccarese, M, Fumagalli, A, Sartori, D, Valerio, M, Airoldi, M, Moretti, G, Ficorella, C, Gianni, L, Michelotti, A, Zambelli, A, Febbraro, A, Generali, D, Pistelli, M, Garrone, O, Musolino, A, Vici, P, Maur, M, Mentuccia, L, La Verde, N, Bianchi, G, Artale, S, Blasi, L, De Laurentiis, M, Atzori, F, Turletti, A, Porpiglia, M, Santini, D, Fabi, A, Gebbia, V, Schirone, A, Palumbo, R, Ferzi, A, Frassoldati, A, Scavelli, C, Clivio, L, Giordano, M, Donadio, M, Biganzoli, L, Del Mastro, L, Bisagni, G, Livi, L, Natoli, C, Montemurro, F, Riccardi, F, Romagnoli, E, Marchetti, P, Torri, V, Pronzato, P, Mustacchi, G, Cazzaniga M. E., Verusio C., Ciccarese M., Fumagalli A., Sartori D., Valerio M. R., Airoldi M., Moretti G., Ficorella C., Gianni L., Michelotti A., Zambelli A., Febbraro A., Generali D., Pistelli M., Garrone O., Musolino A., Vici P., Maur M., Mentuccia L., La Verde N., Bianchi G. V., Artale S., Blasi L., De Laurentiis M., Atzori F., Turletti A., Porpiglia M., Santini D., Fabi A., Gebbia V., Schirone A., Palumbo R., Ferzi A., Frassoldati A., Scavelli C., Clivio L., Giordano M., Donadio M., Biganzoli L., Del Mastro L., Bisagni G., Livi L., Natoli C., Montemurro F., Riccardi F., Romagnoli E., Marchetti P., Torri V., Pronzato P., and Mustacchi G.

Abstract

Background: Different studies suggest that fulvestrant 500 mg every 28 days (HD-FUL) could be an active treatment in HR+ advanced breast cancer (ABC) patients even treated with aromatase inhibitors in the adjuvant setting. The aim of this analysis is to describe the outcome of ABC patients treated with HD-FUL as first-line treatment in terms of median duration of treatment and the overall response rate in a real-world setting. Methods: For the purpose of the present analysis, we considered two data sets of HR+ ABC patients collected in Italy between 2012 and 2015 (EVA and GIM-13 AMBRA studies). Results: Eighty-one and 91 patients have been identified from the two data sets. The median age was 63 years (range 35-82) for the EVA and 57.8 years (range 35.0-82.3) for the AMBRA patients. ORRs were 23.5 and 24.3% in the whole population, 26.9% in the patients with bone only, and 21.8 and 21.4% in those with visceral metastases. The median duration of HD-FUL was 11.6 months (range 1-48) and 12.4 months (range 2.9-70.0) in the two data sets, respectively. Conclusion: These data suggest that HD-FUL should still continue to play a significant role as first-line therapy in HR+ ABC patients.

Published
2020

16. Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study

Author

Basso, U., Paolieri, F., Rizzo, M., De Giorgi, U., Bracarda, S., Antonuzzo, L., Atzori, F., Cartenì, G., Procopio, G., Fratino, L., D’Arcangelo, M., Fornarini, G., Zucali, P., Cusmai, A., Santoni, M., Pipitone, S., Carella, C., Panni, S., Deppieri, F. M., Zagonel, V., and Tortora, Giampaolo

Subjects
Settore MED/06 - ONCOLOGIA MEDICA, cancer
Abstract

This is a retrospective analysis on the safety and activity of compassionate Ipilimumab and Nivolumab (IPI-NIVO) administered to patients with metastatic Renal Cell Carcinoma (mRCC) with intermediate or poor International Metastatic RCC Database Consortium (IMDC) score as a first-line regimen. IPI was infused at 1 mg/kg in combination with Nivolumab 3 mg/kg every three weeks for four doses, followed by maintenance Nivolumab (240 or 480 mg flat dose every two or four weeks, respectively) until disease progression or unacceptable toxicity. A total of 324 patients started IPI-NIVO at 86 Italian centers. Median age was 62 years, 68.2% IMDC intermediate risk. Primary tumor had been removed in 65.1% of patients. Two hundred and twenty patients (67.9%) completed the four IPI-NIVO doses. Investigator-assessed overall response rate was 37.6% (2.8% complete). Twelve-month survival rate was 66.8%, median progression-free survival was 8.3 months. Grade 3 or 4 treatment-related adverse events occurred in 67 patients (26.9%). IMDC intermediate risk, nephrectomy, BMI ≥ 25 kg/m

Published
2022

17. Validation of the Meet-URO score in patients with metastatic renal cell carcinoma receiving first-line nivolumab and ipilimumab in the Italian Expanded Access Program

Author

Rebuzzi, S. E., Signori, A., Buti, S., Banna, G. L., Murianni, V., Damassi, A., Maruzzo, M., Giannarelli, Diana, Tortora, Giampaolo, Galli, L., Rizzo, M., De Giorgi, U., Antonuzzo, L., Bracarda, S., Cartenì, G., Atzori, Francesco, Tamberi, S., Procopio, G., Fratino, L., Lo Re, G., Santoni, M., Baldessari, C., Astone, Antonio, Calabrò, F., Brunelli, M., Porta, C., Rescigno, P., Basso, U., Fornarini, G., Giannarelli D., Tortora G. (ORCID:0000-0002-1378-4962), Atzori F., Astone A. (ORCID:0000-0001-9572-309X), Rebuzzi, S. E., Signori, A., Buti, S., Banna, G. L., Murianni, V., Damassi, A., Maruzzo, M., Giannarelli, Diana, Tortora, Giampaolo, Galli, L., Rizzo, M., De Giorgi, U., Antonuzzo, L., Bracarda, S., Cartenì, G., Atzori, Francesco, Tamberi, S., Procopio, G., Fratino, L., Lo Re, G., Santoni, M., Baldessari, C., Astone, Antonio, Calabrò, F., Brunelli, M., Porta, C., Rescigno, P., Basso, U., Fornarini, G., Giannarelli D., Tortora G. (ORCID:0000-0002-1378-4962), Atzori F., and Astone A. (ORCID:0000-0001-9572-309X)

Abstract

Background: The Meet-URO score allowed a more accurate prognostication than the International Metastatic RCC Database Consortium (IMDC) for patients with pre-treated metastatic renal cell carcinoma (mRCC) by adding the pre-treatment neutrophil-to-lymphocyte ratio and presence of bone metastases.Materials and methods: A post hoc analysis was carried out to validate the Meet-URO score on the overall survival (OS) of patients with IMDC intermediate-poor-risk mRCC treated with first-line nivolumab plus ipilimumab within the prospective Italian Expanded Access Programme (EAP). We additionally considered progression-free survival (PFS) and disease response rates. Harrell's c-index was calculated to compare the accuracy of survival prediction.Results: Overall the EAP included 306 patients, with a median follow-up of 12.2 months, median OS was not reached, 1-year OS was 66.8% and median PFS was 7.9 months. By univariable analysis, both the IMDC score and the two additional variables of the Meet-URO score were associated with either OS or PFS (P < 0.001 for all comparisons). The four Meet-URO risk groups (G) had 1-year OS of 92%, 72%, 50% and 21% for G2 (29.1% of patients), G3 (28.8%), G4 (33.0%) and G5 (9.1%), respectively. OS was significantly shorter in each consecutive G (P = 0.001 for G3, P < 0.001 for both G4 and G5 compared to G2). Similarly, Meet-URO Gs 2-5 showed decreasing median PFS and response rates. The Meet-URO score showed the highest c-index for both OS (0.73) and PFS (0.67). Limitations include the post hoc nature of this analysis and the lack of a comparative arm to assess predictive value.Conclusion: The Meet-URO score appeared to show better prognostic classification than the IMDC alone in patients with mRCC at IMDC intermediate-poor risk treated with first-line nivolumab and ipilimumab.

Published
2022

20. Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

Author

Cicchiello, F., Riva, F., Cazzaniga, M. E., Pedani, F., Nicolini, Matteo, Butti, C., Liscia, N., Pogliani, C., Capri, Giorgia, Alu', Matteo, Febbraro, A., Petrucelli, L., D'Onofrio, L., De Laurentiis, M., Pellegrini, D., Mentuccia, L., Cocciolone, V., Miraglio, E., Bajardi, E., Dester, M., Paternò, Enrico, Guaitoli, G., Ferrarini, I., Gervasi, Elisea, Licata, L., Benedetto, C., Andreis, D., Bordin, E., Ancona, C., Pizzuti, L., Fotia, V., Berardi, R., Airoldi, M., Arcangeli, V., Artale, S., Atzori, F., Ballerio, A., Bianchi, G. V., Blasi, L., Campidoglio, S., Ciccarese, M., Cursano, M. C., Piezzo, M., Fabi, A., Ferrari, L., Ferzi, A., Ficorella, C., Frassoldati, A., Fumagalli, A., Garrone, O., Gebbia, V., Generali, D., La Verde, N., Maur, M., Michelotti, A., Moretti, G., Musolino, Anna, Palumbo, R., Pistelli, M., Porpiglia, M., Sartori, D., Scavelli, C., Schirone, A., Turletti, A., Valerio, M. R., Vici, P., Zambelli, Ruggero Astolfo, Clivio, L., Torri, V., Cicchiello, F, Riva, F, Cazzaniga, M, Pedani, F, Nicolini, M, Butti, C, Liscia, N, Pogliani, C, Capri, G, Alu, M, Febbraro, A, Petrucelli, L, D'Onofrio, L, De Laurentiis, M, Pellegrini, D, Mentuccia, L, Cocciolone, V, Miraglio, E, Bajardi, E, Dester, M, Paterno, E, Guaitoli, G, Ferrarini, I, Gervasi, E, Licata, L, Benedetto, C, Andreis, D, Bordin, E, Ancona, C, Pizzuti, L, Fotia, V, Berardi, R, Airoldi, M, Arcangeli, V, Artale, S, Atzori, F, Ballerio, A, Bianchi, G, Blasi, L, Campidoglio, S, Ciccarese, M, Cursano, M, Piezzo, M, Fabi, A, Ferrari, L, Ferzi, A, Ficorella, C, Frassoldati, A, Fumagalli, A, Garrone, O, Gebbia, V, Generali, D, La Verde, N, Maur, M, Michelotti, A, Moretti, G, Musolino, A, Palumbo, R, Pistelli, M, Porpiglia, M, Sartori, D, Scavelli, C, Schirone, A, Turletti, A, Valerio, M, Vici, P, Zambelli, A, Clivio, L, Torri, V, Cazzaniga, M. E, Bianchi, G. V, Cursano, M. C, Valerio, M. R, Torri, V., De Laurentiis, Michelino, Cicchiello, F., Riva, F., Cazzaniga, M. E., Pedani, F., Nicolini, M., Butti, C., Liscia, N., Pogliani, C., Capri, G., Alù, M., Febbraro, A., Petrucelli, L., D'Onofrio, L., De Laurentiis, M., Pellegrini, D., Mentuccia, L., Cocciolone, V., Miraglio, E., Bajardi, E., Dester, M., Paternò, E., Guaitoli, G., Ferrarini, I., Gervasi, E., Licata, L., Benedetto, C., Andreis, D., Bordin, E., Ancona, C., Pizzuti, L., Fotia, V., Berardi, R., Airoldi, M., Arcangeli, V., Artale, S., Atzori, F., Ballerio, A., Bianchi, G. V., Blasi, L., Campidoglio, S., Ciccarese, M., Cursano, M. C., Piezzo, M., Fabi, A., Ferrari, L., Ferzi, A., Ficorella, C., Frassoldati, A., Fumagalli, A., Garrone, O., Gebbia, V., Generali, D., La Verde, N., Maur, M., Michelotti, A., Moretti, G., Musolino, A., Palumbo, R., Pistelli, M., Porpiglia, M., Sartori, D., Scavelli, C., Schirone, A., Turletti, A., Valerio, M. R., Vici, P., Zambelli, A., Clivio, L., Cazzaniga, M., Ala, M., ARRIVAS BAJARDI, E., Paternã², E., Bianchi, G., Cursano, M., and Valerio, M.

Subjects
0301 basic medicine, Oncology, Receptor, ErbB-2, chemistry.chemical_compound, ErbB-2, 0302 clinical medicine, Dose-intensity, Exemestane, 80 and over, Neoplasm Metastasis, Fulvestrant, Aged, 80 and over, education.field_of_study, Advanced breast cancer, Dose-intensity, Everolimus, Fulvestrant, Hormone-receptor positive, Advanced breast cancer, Everolimus, Hormone-receptor positive, Adult, Aged, Androstadienes, Breast Neoplasms, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Staging, Surgery, General Medicine, Everolimu, 030220 oncology & carcinogenesis, Receptor, medicine.drug, medicine.medical_specialty, Population, Socio-culturale, 03 medical and health sciences, Breast cancer, Internal medicine, medicine, Adverse effect, education, Gynecology, business.industry, fungi, Cancer, medicine.disease, Clinical trial, 030104 developmental biology, chemistry, business
Abstract

Background The BOLERO-2 trial reported efficacy and safety of Everolimus (EVE) and Exemestane (EXE) combination in HR+ advanced breast cancer (ABC) patients. The BALLET trial further evaluated the safety of EVE-EXE in HR+ ABC patients, without reporting efficacy data. Aim of the EVA real-life study was to collect data of efficacy and safety of EVE-EXE combination in the clinical setting, as well as exploring efficacy according to EVE Dose-Intensity (DI) and to previous treatment with Fulvestrant. Patients and methods This study aimed to describe the outcome of ABC pts treated with EVE-EXE combination in terms of median duration of EVE treatment and ORR in a real-life setting. Results From July 2013 to December 2015, the EVA study enrolled 404 pts. Median age was 61 years (33–83). Main metastatic sites were: bone (69.1%), soft tissue (34.7%) and viscera (33.2%). Median number of previous treatments was 2 (1–7). 43.3% of the pts had received Fulvestrant. Median exposure to EVE was 31.0 weeks (15.4–58.3) in the whole population. No difference was observed in terms of EVE exposure duration according to DI (p for trend = 0.27) or type of previous treatments (p = 0.33). ORR and Disease Control Rate (DCR) were observed in 31.6% and 60.7% of the patients, respectively, with the lowest ORRs confined in CHT pre-treated patients or in those who received the lowest DI of EVE. Grade 3-4 adverse events (AEs) were reported in 37.9% of the patients. Main AEs were: stomatitis (11.2%), non-infectious pneumonitis - NIP (3.8%), anaemia (3.8%) and fatigue (3.2%). Conclusions The EVA study provided new insights in the use of EVE-EVE combination in HR+ ABC pts many years after the publication of the pivotal trial. The combination is safe and the best response could be obtained in patients receiving the full dose of EVE and/or after hormone-therapy as Fulvestrant in ABC.

Published
2017

21. Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success

Author

Cazzaniga, M, Danesi, R, Girmenia, C, Invernizzi, P, Elvevi, A, Uguccioni, M, Amaducci, L, Atzori, F, Blasi, L, Butti, C, Collova, E, De Conciliis, E, Fabi, A, Febbraro, A, Garrone, O, Gianni, L, Giotta, F, La Verde, N, Michelotti, A, Palumbo, R, Paris, I, Pistelli, M, Pizzuti, L, Rubino, D, Valerio, M, Zustovich, F, Cazzaniga M. E., Danesi R., Girmenia C., Invernizzi P., Elvevi A., Uguccioni M., Amaducci L., Atzori F., Blasi L., Butti C., Collova E., De Conciliis E., Fabi A., Febbraro A., Garrone O., Gianni L., Giotta F., La Verde N., Michelotti A., Palumbo R., Paris I., Pistelli M., Pizzuti L., Rubino D., Valerio M. R., Zustovich F., Cazzaniga, M, Danesi, R, Girmenia, C, Invernizzi, P, Elvevi, A, Uguccioni, M, Amaducci, L, Atzori, F, Blasi, L, Butti, C, Collova, E, De Conciliis, E, Fabi, A, Febbraro, A, Garrone, O, Gianni, L, Giotta, F, La Verde, N, Michelotti, A, Palumbo, R, Paris, I, Pistelli, M, Pizzuti, L, Rubino, D, Valerio, M, Zustovich, F, Cazzaniga M. E., Danesi R., Girmenia C., Invernizzi P., Elvevi A., Uguccioni M., Amaducci L., Atzori F., Blasi L., Butti C., Collova E., De Conciliis E., Fabi A., Febbraro A., Garrone O., Gianni L., Giotta F., La Verde N., Michelotti A., Palumbo R., Paris I., Pistelli M., Pizzuti L., Rubino D., Valerio M. R., and Zustovich F.

Abstract

Purpose: Agents targeting HR-positive, HER2-negative locally advanced or metastatic breast cancer have improved patient outcomes compared with conventional single-agent endocrine therapy. Currently, approved targeted agents include everolimus and three CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib. Unlike the well-characterized and easily manageable safety profile of endocrine therapies, adverse events associated with targeted therapies are complex and potentially severe. Their prompt recognition and treatment, crucial for prolonged endocrine sensitivity and survival, may be challenging and requires a multidisciplinary effort and a good knowledge of drug interactions. Methods: We reviewed the current evidence on the drug safety of targeted agents for metastatic breast cancer currently used in clinical practice in Italy, supported by the clinical experience of Italian oncologists with expertise in the field. Results: All oncologists had used CDK4/6 inhibitors in clinical practice and/or within a clinical trial. The clinical management of toxicities, including dose adjustments, treatment interruptions, and concerns regarding special populations is discussed, and the management of relevant adverse events, related to individual agents and class-specific, toxicities is reviewed. Hematologic toxicities have the greatest impact on clinical management of the disease and on patients. Although toxicities associated with the new treatments result in more visits to the physician and more time and attention with patients, they are manageable, with no need for the oncologist to consult with specialist physicians. Conclusions: Based on the available evidence and current guidelines, we propose a series of practical recommendations for multidisciplinary clinical management of the various toxicities associated with the addition of targeted agents to endocrine therapy.

Published
2019

22. Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success

Author

Cazzaniga M. E., Danesi R., Girmenia C., Invernizzi P., Elvevi A., Uguccioni M., Amaducci L., Atzori F., Blasi L., Butti C., Collova E., De Conciliis E., Fabi A., Febbraro A., Garrone O., Gianni L., Giotta F., La Verde N., Michelotti A., Palumbo R., Paris I., Pistelli M., Pizzuti L., Rubino D., Valerio M. R., Zustovich F., Cazzaniga M.E., Danesi R., Girmenia C., Invernizzi P., Elvevi A., Uguccioni M., Amaducci L., Atzori F., Blasi L., Butti C., Collova E., De Conciliis E., Fabi A., Febbraro A., Garrone O., Gianni L., Giotta F., La Verde N., Michelotti A., Palumbo R., Paris I., Pistelli M., Pizzuti L., Rubino D., Valerio M.R., Zustovich F., Cazzaniga, M, Danesi, R, Girmenia, C, Invernizzi, P, Elvevi, A, Uguccioni, M, Amaducci, L, Atzori, F, Blasi, L, Butti, C, Collova, E, De Conciliis, E, Fabi, A, Febbraro, A, Garrone, O, Gianni, L, Giotta, F, La Verde, N, Michelotti, A, Palumbo, R, Paris, I, Pistelli, M, Pizzuti, L, Rubino, D, Valerio, M, and Zustovich, F

Subjects
0301 basic medicine, Cancer Research, Review, Disease, chemistry.chemical_compound, 0302 clinical medicine, Ribociclib, Molecular Targeted Therapy, Abemaciclib, Clinical Trials as Topic, Disease Management, Metastatic breast cancer, Everolimu, Oncology, Receptors, Estrogen, 030220 oncology & carcinogenesis, Female, Advanced breast cancer, Receptors, Progesterone, Breast Neoplasm, medicine.drug, Human, medicine.medical_specialty, Neutropenia, Drug-Related Side Effects and Adverse Reactions, Antineoplastic Agents, Hormonal, Protein Kinase Inhibitor, Breast Neoplasms, Palbociclib, 03 medical and health sciences, Breast cancer, medicine, Biomarkers, Tumor, Humans, Everolimus, Intensive care medicine, Adverse effect, Protein Kinase Inhibitors, business.industry, medicine.disease, Clinical trial, 030104 developmental biology, chemistry, MED/06 - ONCOLOGIA MEDICA, business, Drug-Related Side Effects and Adverse Reaction
Abstract

Purpose: Agents targeting HR-positive, HER2-negative locally advanced or metastatic breast cancer have improved patient outcomes compared with conventional single-agent endocrine therapy. Currently, approved targeted agents include everolimus and three CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib. Unlike the well-characterized and easily manageable safety profile of endocrine therapies, adverse events associated with targeted therapies are complex and potentially severe. Their prompt recognition and treatment, crucial for prolonged endocrine sensitivity and survival, may be challenging and requires a multidisciplinary effort and a good knowledge of drug interactions. Methods: We reviewed the current evidence on the drug safety of targeted agents for metastatic breast cancer currently used in clinical practice in Italy, supported by the clinical experience of Italian oncologists with expertise in the field. Results: All oncologists had used CDK4/6 inhibitors in clinical practice and/or within a clinical trial. The clinical management of toxicities, including dose adjustments, treatment interruptions, and concerns regarding special populations is discussed, and the management of relevant adverse events, related to individual agents and class-specific, toxicities is reviewed. Hematologic toxicities have the greatest impact on clinical management of the disease and on patients. Although toxicities associated with the new treatments result in more visits to the physician and more time and attention with patients, they are manageable, with no need for the oncologist to consult with specialist physicians. Conclusions: Based on the available evidence and current guidelines, we propose a series of practical recommendations for multidisciplinary clinical management of the various toxicities associated with the addition of targeted agents to endocrine therapy.

Published
2019

24. 696P Is it possible to improve the prognostic ability of the IMDC score? Validation of the Meet-URO score in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line nivolumab plus ipilimumab in the Italian Expanded Access Program (EAP)

Author

Rebuzzi, S.E., primary, Signori, A., additional, Maruzzo, M., additional, Tortora, G., additional, Galli, L., additional, Rizzo, M., additional, De Giorgi, U., additional, Antonuzzo, L., additional, Bracarda, S., additional, Cartenì, G., additional, Atzori, F., additional, Tamberi, S., additional, Procopio, G., additional, Fratino, L., additional, Santoni, M., additional, Baldessari, C., additional, Astone, A., additional, Calabro', F., additional, Buti, S., additional, and Fornarini, G., additional

Published
2021
Full Text
View/download PDF

28. 1884MO Phase II study of avelumab (Ave) plus intermittent axitinib (Axi) in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC): The TIDE-A study

Author

Iacovelli, R., Ciccarese, C., Bersanelli, M., Zucali, P.A., Fantinel, E., Bimbatti, D., Verzoni, E., Accettura, C., Bonomi, L., Buttigliero, C., G. fornarini, Pipitone, S., Atzori, F., Masini, C., Massari, F., Primi, F., Buti, S., Perrino, M.R.A., Pafumi, S., and Tortora, G.

Published
2023
Full Text
View/download PDF

30. Epifisiolisi

Author

Massè, A., Aprato, A., Favuto, M., Atzori, F., Nicodemo, A., and Governale, G.

Published
2010
Full Text
View/download PDF

31. Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study

Author

Cazzaniga, M., Verusio, C., Ciccarese, M., Fumagalli, A., Sartori, D., Ancona, C., Airoldi, M., Moretti, G., Ficorella, C., Arcangeli, V., Diodati, L., Zambelli, A., Febbraro, A., Generali, D., Pistelli, M., Garrone, O., Musolino, A., Vici, P., Maur, M., Mentuccia, L., La Verde, N., Bianchi, G., Artale, S., Blasi, L., Piezzo, M., Atzori, F., Turletti, A., Benedetto, C., Cursano, M. C., Fabi, A., Gebbia, V., Schirone, A., Palumbo, R., Ferzi, A., Frassoldati, A., Scavelli, C., Clivio, L., Torri, V., On behalf of The EVA Study Group, Cazzaniga, Marina, Verusio, Claudio, Ciccarese, Mariangela, Fumagalli, Alberto, Sartori, Donata, D'Ancona, Cristina, Airoldi, Mario, Moretti, Gabriella, Ficorella, Corrado, Arcangeli, Valentina, Diodati, Lucrezia, Zambelli, Alberto, Febbraro, Antonio, Generali, Daniele, Pistelli, Mirco, Garrone, Ornella, Musolino, Antonino, Vici, Patrizia, Maur, Michela, Mentuccia, Lucia, La Verde, Nicla, Bianchi, Giulia, Artale, Salvatore, Blasi, Livio, Piezzo, Matilde, Atzori, Francesco, Turletti, Anna, Benedetto, Chiara, Cursano, Maria Concetta, Fabi, Alessandra, Gebbia, Vittorio, Schirone, Antonio, Palumbo, Raffaella, Ferzi, Antonella, Frassoldati, Antonio, Scavelli, Claudio, Clivio, Luca, Torri, Valter, Cazzaniga, M, Verusio, C, Ciccarese, M, Fumagalli, A, Sartori, D, Ancona, C, Airoldi, M, Moretti, G, Ficorella, C, Arcangeli, V, Diodati, L, Zambelli, A, Febbraro, A, Generali, D, Pistelli, M, Garrone, O, Musolino, A, Vici, P, Maur, M, Mentuccia, L, La Verde, N, Bianchi, G, Artale, S, Blasi, L, Piezzo, M, Atzori, F, Turletti, A, Benedetto, C, Cursano, M, Fabi, A, Gebbia, V, Schirone, A, Palumbo, R, Ferzi, A, Frassoldati, A, Scavelli, C, Clivio, L, Torri, V, On behalf of The EVA Study, G, Cazzaniga M., Verusio C., Ciccarese M., Fumagalli A., Sartori D., Valerio MR., Airoldi M., Moretti G., Ficorella C., Arcangeli V., Diodati L., Zambelli A., Febbraro A., Generali D., Pistelli M., Garrone O., Musolino A., Vici P., Maur M., Mentuccia L., La Verde N., Bianchi G., Artale S., Blasi L., Piezzo M., Atzori F., Turletti A., Benedetto C., Cursano M.C., Fabi A., Gebbia V., Schirone A., Palumbo R., Ferzi A., Frassoldati A., Scavelli C., Clivio L., Torri V., and On behalf of The EVA Study Group

Subjects
medicine.medical_specialty, Socio-culturale, Hormone-receptor positive, Exemestane, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Breast cancer, Elderly, Weight loss, Internal medicine, Advanced breast cancer, Everolimus, Oncology, medicine, 030212 general & internal medicine, Stomatitis, Pneumonitis, business.industry, Cancer, medicine.disease, Rash, Everolimu, chemistry, 030220 oncology & carcinogenesis, MED/06 - ONCOLOGIA MEDICA, medicine.symptom, business, Research Paper, medicine.drug
Abstract

BACKGROUND: The present analysis focuses on real-world data of Everolimus- Exemestane in advanced HR+ve, HER2-ve elderly breast cancer patients (aged 65 years) included in the EVA study, with unique findings in those aged 70 years. METHODS: Data are collected from clinical records and analysed according to age cut-off (< 65 years; 65 - 69 years and [greater than or equal to] 70 years). Relationship of analyzed variables with response were tested by mean of a Mantel- Haenszel chi square test. Time to event analysis was described by Kaplan Meier approach and association with baseline characteristics was analysed by stratified log-rank test and proportional hazard model. RESULTS: From July 2013 to December 2015, the EVA study enrolled overall 404 pts. 154 patients out of 404 (38,1%) were aged [greater than or equal to] 65 years, of whom 87 were [greater than or equal to] 70 years. Median duration of EVE treatment was 28.5 weeks (95% CI 19.0 - 33.8) in patients aged 65-69 years and 24,4 weeks (95% CI 19,2 - 33,2) in those aged [greater than or equal to] 70 years. Fewer patients aged 65 years received the highest EVE Dose-Intensity (> 7.5 mg/day) in comparison to younger patients (49,6% vs. 66,8%). Grade 3-4 toxicities occurred to 55 patients (35,7%), mainly stomatitis (10,9%), rash (5,8%) and non-infectious pneumonitis (NIP) (3,6%). Some toxicities, such as weight loss and anaemia were peculiarly observed in patients aged [greater than or equal to] 70 years. Five treatment-related deaths were collected (3,2%). CONCLUSIONS: EVE-EXE combination remains one of the potential treatments in HR+ patients also for elderly ones.

Published
2018

32. Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study

Author

Cazzaniga, M, Verusio, C, Ciccarese, M, Fumagalli, A, Sartori, D, Ancona, C, Airoldi, M, Moretti, G, Ficorella, C, Arcangeli, V, Diodati, L, Zambelli, A, Febbraro, A, Generali, D, Pistelli, M, Garrone, O, Musolino, A, Vici, P, Maur, M, Mentuccia, L, La Verde, N, Bianchi, G, Artale, S, Blasi, L, Piezzo, M, Atzori, F, Turletti, A, Benedetto, C, Cursano, M, Fabi, A, Gebbia, V, Schirone, A, Palumbo, R, Ferzi, A, Frassoldati, A, Scavelli, C, Clivio, L, Torri, V, On behalf of The EVA Study, G, Cazzaniga M., Verusio C., Ciccarese M., Fumagalli A., Sartori D., Ancona C., Airoldi M., Moretti G., Ficorella C., Arcangeli V., Diodati L., Zambelli A., Febbraro A., Generali D., Pistelli M., Garrone O., Musolino A., Vici P., Maur M., Mentuccia L., La Verde N., Bianchi G., Artale S., Blasi L., Piezzo M., Atzori F., Turletti A., Benedetto C., Cursano M. C., Fabi A., Gebbia V., Schirone A., Palumbo R., Ferzi A., Frassoldati A., Scavelli C., Clivio L., Torri V., On behalf of The EVA Study Group, Cazzaniga, M, Verusio, C, Ciccarese, M, Fumagalli, A, Sartori, D, Ancona, C, Airoldi, M, Moretti, G, Ficorella, C, Arcangeli, V, Diodati, L, Zambelli, A, Febbraro, A, Generali, D, Pistelli, M, Garrone, O, Musolino, A, Vici, P, Maur, M, Mentuccia, L, La Verde, N, Bianchi, G, Artale, S, Blasi, L, Piezzo, M, Atzori, F, Turletti, A, Benedetto, C, Cursano, M, Fabi, A, Gebbia, V, Schirone, A, Palumbo, R, Ferzi, A, Frassoldati, A, Scavelli, C, Clivio, L, Torri, V, On behalf of The EVA Study, G, Cazzaniga M., Verusio C., Ciccarese M., Fumagalli A., Sartori D., Ancona C., Airoldi M., Moretti G., Ficorella C., Arcangeli V., Diodati L., Zambelli A., Febbraro A., Generali D., Pistelli M., Garrone O., Musolino A., Vici P., Maur M., Mentuccia L., La Verde N., Bianchi G., Artale S., Blasi L., Piezzo M., Atzori F., Turletti A., Benedetto C., Cursano M. C., Fabi A., Gebbia V., Schirone A., Palumbo R., Ferzi A., Frassoldati A., Scavelli C., Clivio L., Torri V., and On behalf of The EVA Study Group

Abstract

BACKGROUND: The present analysis focuses on real-world data of Everolimus- Exemestane in advanced HR+ve, HER2-ve elderly breast cancer patients (aged 65 years) included in the EVA study, with unique findings in those aged 70 years. METHODS: Data are collected from clinical records and analysed according to age cut-off (< 65 years; 65 - 69 years and [greater than or equal to] 70 years). Relationship of analyzed variables with response were tested by mean of a Mantel- Haenszel chi square test. Time to event analysis was described by Kaplan Meier approach and association with baseline characteristics was analysed by stratified log-rank test and proportional hazard model. RESULTS: From July 2013 to December 2015, the EVA study enrolled overall 404 pts. 154 patients out of 404 (38,1%) were aged [greater than or equal to] 65 years, of whom 87 were [greater than or equal to] 70 years. Median duration of EVE treatment was 28.5 weeks (95% CI 19.0 - 33.8) in patients aged 65-69 years and 24,4 weeks (95% CI 19,2 - 33,2) in those aged [greater than or equal to] 70 years. Fewer patients aged 65 years received the highest EVE Dose-Intensity (> 7.5 mg/day) in comparison to younger patients (49,6% vs. 66,8%). Grade 3-4 toxicities occurred to 55 patients (35,7%), mainly stomatitis (10,9%), rash (5,8%) and non-infectious pneumonitis (NIP) (3,6%). Some toxicities, such as weight loss and anaemia were peculiarly observed in patients aged [greater than or equal to] 70 years. Five treatment-related deaths were collected (3,2%). CONCLUSIONS: EVE-EXE combination remains one of the potential treatments in HR+ patients also for elderly ones.

Published
2018

33. Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874)

Author

Cazzaniga M., Cazzaniga, M, Verusio, C, Ciccarese, M, Fumagalli, A, Sartori, D, Valerio, M, Airoldi, M, Moretti, G, Ficorella, C, Arcangeli, V, Diodati, L, Zambelli, A, Febbraro, A, Generali, D, Pistelli, M, Garrone, O, Musolino, A, Vici, P, Maur, M, Mentuccia, L, La Verde, N, Bianchi, G, Artale, S, Blasi, L, Piezzo, M, Atzori, F, Turletti, A, Benedetto, C, Cursano, M, Fabi, A, Gebbia, V, Schirone, A, Palumbo, R, Ferzi, A, Frassoldati, A, Scavelli, C, Clivio, L, Torri, V, Cazzaniga M., Verusio C., Ciccarese M., Fumagalli A., Sartori D., Valerio M. R., Airoldi M., Moretti G., Ficorella C., Arcangeli V., Diodati L., Zambelli A., Febbraro A., Generali D., Pistelli M., Garrone O., Musolino A., Vici P., Maur M., Mentuccia L., La Verde N., Bianchi G., Artale S., Blasi L., Piezzo M., Atzori F., Turletti A., Benedetto C., Cursano M. C., Fabi A., Gebbia V., Schirone A., Palumbo R., Ferzi A., Frassoldati A., Scavelli C., Clivio L., Torri V., Cazzaniga M., Cazzaniga, M, Verusio, C, Ciccarese, M, Fumagalli, A, Sartori, D, Valerio, M, Airoldi, M, Moretti, G, Ficorella, C, Arcangeli, V, Diodati, L, Zambelli, A, Febbraro, A, Generali, D, Pistelli, M, Garrone, O, Musolino, A, Vici, P, Maur, M, Mentuccia, L, La Verde, N, Bianchi, G, Artale, S, Blasi, L, Piezzo, M, Atzori, F, Turletti, A, Benedetto, C, Cursano, M, Fabi, A, Gebbia, V, Schirone, A, Palumbo, R, Ferzi, A, Frassoldati, A, Scavelli, C, Clivio, L, Torri, V, Cazzaniga M., Verusio C., Ciccarese M., Fumagalli A., Sartori D., Valerio M. R., Airoldi M., Moretti G., Ficorella C., Arcangeli V., Diodati L., Zambelli A., Febbraro A., Generali D., Pistelli M., Garrone O., Musolino A., Vici P., Maur M., Mentuccia L., La Verde N., Bianchi G., Artale S., Blasi L., Piezzo M., Atzori F., Turletti A., Benedetto C., Cursano M. C., Fabi A., Gebbia V., Schirone A., Palumbo R., Ferzi A., Frassoldati A., Scavelli C., Clivio L., and Torri V.

Abstract

This article has been corrected: The correct author names are given below: Chiara Ancona and Michela Piezzo.

Published
2018

34. Erratum: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9 (31877-31887) DOI: 10.18632/oncotarget.25874)

Author

Cazzaniga M., Cazzaniga, M, Verusio, C, Ciccarese, M, Fumagalli, A, Sartori, D, Valerio, M, Airoldi, M, Moretti, G, Ficorella, C, Arcangeli, V, Diodati, L, Zambelli, A, Febbraro, A, Generali, D, Pistelli, M, Garrone, O, Musolino, A, Vici, P, Maur, M, Mentuccia, L, La Verde, N, Bianchi, G, Artale, S, Blasi, L, Piezzo, M, Atzori, F, Turletti, A, Benedetto, C, Cursano, M, Fabi, A, Gebbia, V, Schirone, A, Palumbo, R, Ferzi, A, Frassoldati, A, Scavelli, C, Clivio, L, Torri, V, Cazzaniga M., Verusio C., Ciccarese M., Fumagalli A., Sartori D., Valerio M. R., Airoldi M., Moretti G., Ficorella C., Arcangeli V., Diodati L., Zambelli A., Febbraro A., Generali D., Pistelli M., Garrone O., Musolino A., Vici P., Maur M., Mentuccia L., La Verde N., Bianchi G., Artale S., Blasi L., Piezzo M., Atzori F., Turletti A., Benedetto C., Cursano M. C., Fabi A., Gebbia V., Schirone A., Palumbo R., Ferzi A., Frassoldati A., Scavelli C., Clivio L., Torri V., Cazzaniga M., Cazzaniga, M, Verusio, C, Ciccarese, M, Fumagalli, A, Sartori, D, Valerio, M, Airoldi, M, Moretti, G, Ficorella, C, Arcangeli, V, Diodati, L, Zambelli, A, Febbraro, A, Generali, D, Pistelli, M, Garrone, O, Musolino, A, Vici, P, Maur, M, Mentuccia, L, La Verde, N, Bianchi, G, Artale, S, Blasi, L, Piezzo, M, Atzori, F, Turletti, A, Benedetto, C, Cursano, M, Fabi, A, Gebbia, V, Schirone, A, Palumbo, R, Ferzi, A, Frassoldati, A, Scavelli, C, Clivio, L, Torri, V, Cazzaniga M., Verusio C., Ciccarese M., Fumagalli A., Sartori D., Valerio M. R., Airoldi M., Moretti G., Ficorella C., Arcangeli V., Diodati L., Zambelli A., Febbraro A., Generali D., Pistelli M., Garrone O., Musolino A., Vici P., Maur M., Mentuccia L., La Verde N., Bianchi G., Artale S., Blasi L., Piezzo M., Atzori F., Turletti A., Benedetto C., Cursano M. C., Fabi A., Gebbia V., Schirone A., Palumbo R., Ferzi A., Frassoldati A., Scavelli C., Clivio L., and Torri V.

Abstract

This article has been corrected: The correct author name is given below:.

Published
2018

35. Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial

Author

Mennitto, A., primary, Verzoni, E., additional, Cognetti, F., additional, Miceli, R., additional, Milella, M., additional, Mosca, A., additional, Chiuri, V. E., additional, Bearz, A., additional, Morelli, F., additional, Ortega, C., additional, Atzori, F., additional, Donini, M., additional, Claps, M., additional, Guadalupi, V., additional, Sepe, P., additional, Cappelletti, V., additional, de Braud, F. G., additional, and Procopio, G., additional

Published
2021
Full Text
View/download PDF

37. 800TiP Meet-URO 12: A randomized phase II trial of niraparib versus best supportive care (BSC) as maintenance treatment in patients with locally advanced or metastatic urothelial cancer (UC) whose disease did not progress after completion of first-line platinum-based chemotherapy

Author

Vignani, F., primary, Hamzaj, A., additional, De Giorgi, U., additional, Tambaro, R., additional, Basso, U., additional, Gamba, T., additional, Ermacora, P., additional, Santini, D., additional, Capacci, S., additional, Casadei, C., additional, Pignata, S., additional, Bimbatti, D., additional, Giannatempo, P., additional, Atzori, F., additional, Cavanna, L., additional, Veccia, A., additional, Scandurra, G., additional, Doni, L., additional, Aieta, M., additional, and Di Maio, M., additional

Published
2020
Full Text
View/download PDF

38. 721P Ipilimumab and nivolumab compassionate use program in metastatic renal cell carcinoma patients with intermediate or poor IMDC risk score: The large multicenter Italian study

Author

Basso, U., primary, Paolieri, F., additional, Porta, C.G., additional, De Giorgi, U., additional, Bracarda, S., additional, Antonuzzo, L., additional, Atzori, F., additional, Cartenì, G., additional, Procopio, G., additional, Fratino, L., additional, D'Arcangelo, M., additional, Fornarini, G., additional, Zucali, P.A., additional, Cusmai, A., additional, Santoni, M., additional, Baldessari, C., additional, Naglieri, E., additional, Panni, S., additional, Zagonel, V., additional, and Tortora, G., additional

Published
2020
Full Text
View/download PDF

39. 736P Updated data on patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sorafenib (SOR) vs observation (obs) after radical metastasectomy in the RESORT trial

Author

Procopio, G., primary, Cognetti, F., additional, Miceli, R., additional, Milella, M., additional, Mosca, A., additional, Chiuri, V.E., additional, Bearz, A., additional, Morelli, F., additional, Ortega, C., additional, Atzori, F., additional, Donini, M., additional, Passalacqua, R., additional, Mennitto, A., additional, Sepe, P., additional, Martinetti, A., additional, Montone, R., additional, Apollonio, G., additional, Guadalupi, V., additional, Verzoni, E., additional, and Claps, M., additional

Published
2020
Full Text
View/download PDF

40. Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

Author

Cicchiello, F, Riva, F, Cazzaniga, M, Pedani, F, Nicolini, M, Butti, C, Liscia, N, Pogliani, C, Capri, G, Alu, M, Febbraro, A, Petrucelli, L, D'Onofrio, L, De Laurentiis, M, Pellegrini, D, Mentuccia, L, Cocciolone, V, Miraglio, E, Bajardi, E, Dester, M, Paterno, E, Guaitoli, G, Ferrarini, I, Gervasi, E, Licata, L, Benedetto, C, Andreis, D, Bordin, E, Ancona, C, Pizzuti, L, Fotia, V, Berardi, R, Airoldi, M, Arcangeli, V, Artale, S, Atzori, F, Ballerio, A, Bianchi, G, Blasi, L, Campidoglio, S, Ciccarese, M, Cursano, M, Piezzo, M, Fabi, A, Ferrari, L, Ferzi, A, Ficorella, C, Frassoldati, A, Fumagalli, A, Garrone, O, Gebbia, V, Generali, D, La Verde, N, Maur, M, Michelotti, A, Moretti, G, Musolino, A, Palumbo, R, Pistelli, M, Porpiglia, M, Sartori, D, Scavelli, C, Schirone, A, Turletti, A, Valerio, M, Vici, P, Zambelli, A, Clivio, L, Torri, V, Cicchiello F., Riva F., Cazzaniga M. E., Pedani F., Nicolini M., Butti C., Liscia N., Pogliani C., Capri G., Alu M., Febbraro A., Petrucelli L., D'Onofrio L., De Laurentiis M., Pellegrini D., Mentuccia L., Cocciolone V., Miraglio E., Bajardi E., Dester M., Paterno E., Guaitoli G., Ferrarini I., Gervasi E., Licata L., Benedetto C., Andreis D., Bordin E., Ancona C., Pizzuti L., Fotia V., Berardi R., Airoldi M., Arcangeli V., Artale S., Atzori F., Ballerio A., Bianchi G. V., Blasi L., Campidoglio S., Ciccarese M., Cursano M. C., Piezzo M., Fabi A., Ferrari L., Ferzi A., Ficorella C., Frassoldati A., Fumagalli A., Garrone O., Gebbia V., Generali D., La Verde N., Maur M., Michelotti A., Moretti G., Musolino A., Palumbo R., Pistelli M., Porpiglia M., Sartori D., Scavelli C., Schirone A., Turletti A., Valerio M. R., Vici P., Zambelli A., Clivio L., Torri V., Cicchiello, F, Riva, F, Cazzaniga, M, Pedani, F, Nicolini, M, Butti, C, Liscia, N, Pogliani, C, Capri, G, Alu, M, Febbraro, A, Petrucelli, L, D'Onofrio, L, De Laurentiis, M, Pellegrini, D, Mentuccia, L, Cocciolone, V, Miraglio, E, Bajardi, E, Dester, M, Paterno, E, Guaitoli, G, Ferrarini, I, Gervasi, E, Licata, L, Benedetto, C, Andreis, D, Bordin, E, Ancona, C, Pizzuti, L, Fotia, V, Berardi, R, Airoldi, M, Arcangeli, V, Artale, S, Atzori, F, Ballerio, A, Bianchi, G, Blasi, L, Campidoglio, S, Ciccarese, M, Cursano, M, Piezzo, M, Fabi, A, Ferrari, L, Ferzi, A, Ficorella, C, Frassoldati, A, Fumagalli, A, Garrone, O, Gebbia, V, Generali, D, La Verde, N, Maur, M, Michelotti, A, Moretti, G, Musolino, A, Palumbo, R, Pistelli, M, Porpiglia, M, Sartori, D, Scavelli, C, Schirone, A, Turletti, A, Valerio, M, Vici, P, Zambelli, A, Clivio, L, Torri, V, Cicchiello F., Riva F., Cazzaniga M. E., Pedani F., Nicolini M., Butti C., Liscia N., Pogliani C., Capri G., Alu M., Febbraro A., Petrucelli L., D'Onofrio L., De Laurentiis M., Pellegrini D., Mentuccia L., Cocciolone V., Miraglio E., Bajardi E., Dester M., Paterno E., Guaitoli G., Ferrarini I., Gervasi E., Licata L., Benedetto C., Andreis D., Bordin E., Ancona C., Pizzuti L., Fotia V., Berardi R., Airoldi M., Arcangeli V., Artale S., Atzori F., Ballerio A., Bianchi G. V., Blasi L., Campidoglio S., Ciccarese M., Cursano M. C., Piezzo M., Fabi A., Ferrari L., Ferzi A., Ficorella C., Frassoldati A., Fumagalli A., Garrone O., Gebbia V., Generali D., La Verde N., Maur M., Michelotti A., Moretti G., Musolino A., Palumbo R., Pistelli M., Porpiglia M., Sartori D., Scavelli C., Schirone A., Turletti A., Valerio M. R., Vici P., Zambelli A., Clivio L., and Torri V.

Abstract

Background The BOLERO-2 trial reported efficacy and safety of Everolimus (EVE) and Exemestane (EXE) combination in HR+ advanced breast cancer (ABC) patients. The BALLET trial further evaluated the safety of EVE-EXE in HR+ ABC patients, without reporting efficacy data. Aim of the EVA real-life study was to collect data of efficacy and safety of EVE-EXE combination in the clinical setting, as well as exploring efficacy according to EVE Dose-Intensity (DI) and to previous treatment with Fulvestrant. Patients and methods This study aimed to describe the outcome of ABC pts treated with EVE-EXE combination in terms of median duration of EVE treatment and ORR in a real-life setting. Results From July 2013 to December 2015, the EVA study enrolled 404 pts. Median age was 61 years (33–83). Main metastatic sites were: bone (69.1%), soft tissue (34.7%) and viscera (33.2%). Median number of previous treatments was 2 (1–7). 43.3% of the pts had received Fulvestrant. Median exposure to EVE was 31.0 weeks (15.4–58.3) in the whole population. No difference was observed in terms of EVE exposure duration according to DI (p for trend = 0.27) or type of previous treatments (p = 0.33). ORR and Disease Control Rate (DCR) were observed in 31.6% and 60.7% of the patients, respectively, with the lowest ORRs confined in CHT pre-treated patients or in those who received the lowest DI of EVE. Grade 3-4 adverse events (AEs) were reported in 37.9% of the patients. Main AEs were: stomatitis (11.2%), non-infectious pneumonitis - NIP (3.8%), anaemia (3.8%) and fatigue (3.2%). Conclusions The EVA study provided new insights in the use of EVE-EVE combination in HR+ ABC pts many years after the publication of the pivotal trial. The combination is safe and the best response could be obtained in patients receiving the full dose of EVE and/or after hormone-therapy as Fulvestrant in ABC.

Published
2017

46. Clinical outcome after radical metastasectomy in renal cell carcinoma: Results from a randomized phase 2 study

Author

Procopio, G., primary, Apollonio, G., additional, Cognetti, F., additional, Miceli, R., additional, Milella, M., additional, Mosca, A., additional, Chiuri, V.E., additional, Bearz, A., additional, Morelli, F., additional, Ortega, C., additional, Atzori, F., additional, Donini, M., additional, Ratta, R., additional, Raimondi, A., additional, Claps, M., additional, Martinetti, A., additional, Capitanio, U., additional, De Braud, F.G., additional, Cappelletti, V., additional, and Verzoni, E., additional

Published
2019
Full Text
View/download PDF

47. Turtles on the trash track: loggerhead turtles exposed to floating plastic in the Mediterranean Sea

Author

Arcangeli, A, primary, Maffucci, F, additional, Atzori, F, additional, Azzolin, M, additional, Campana, I, additional, Carosso, L, additional, Crosti, R, additional, Frau, F, additional, David, L, additional, Di-Méglio, N, additional, Roul, M, additional, Gregorietti, M, additional, Mazzucato, V, additional, Pellegrino, G, additional, Giacoletti, A, additional, Paraboschi, M, additional, Zampollo, A, additional, de Lucia, GA, additional, and Hochscheid, S, additional

Published
2019
Full Text
View/download PDF

48. Efficacy and safety of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in non-metastatic HER2-positive breast cancer in real life: NEOPEARL study

Author

Fabbri, M.A., primary, Botticelli, A., additional, Omarini, C., additional, Cretella, E., additional, Fabi, A., additional, Alesini, D., additional, Pizzuti, L., additional, Piesco, G., additional, Vaccaro, A., additional, Atzori, F., additional, Piacentini, F., additional, Moscetti, L., additional, Orlandi, A., additional, Sini, V., additional, Mercanti, A., additional, Framarino, M.L., additional, Persano, M., additional, Ceccherini, R., additional, and Ruggeri, E.M., additional

Published
2019
Full Text
View/download PDF

49. Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience

Author

Pretta, A., primary, Lai, E., additional, Liscia, N., additional, Impera, V., additional, Camera, S., additional, Musio, F., additional, Mariani, S., additional, Soro, P., additional, Persano, M., additional, Donisi, C., additional, Tolu, S., additional, Balconi, F., additional, Atzori, F., additional, Dessì, M., additional, Massa, E., additional, Madeddu, C., additional, Pusceddu, V., additional, Astara, G., additional, Demurtas, L., additional, Puzzoni, M., additional, Ziranu, P., additional, and Scartozzi, M., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results